International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

A Review on Invitro Evolution of Glimepiride Tablets

Manoj Sarjerao Doiphode[1], Vikas Bhausaheb Wamne[2]

[1]Student, Pratibhatai Pawar College of Pharmacy, Shrirampur.
[2]Assistant Professor, Pratibhatai Pawar College of Pharmacy, Shrirampur.

Abstract:

Type 2 diabetes mellitus is characterised via way of means of insulin resistance and innovative β mobileular Failure; therefore, β mobileular secretagogues are beneficial for attaining enough glycemic control. Glimepiride is a second-era sulfonylurea that stimulates pancreatic β cells to launch Insulin. Additionally, is has been proven to paintings thru numerous more pancreatic mechanisms. It Is administered as monotherapy in sufferers with kind 2 diabetes mellitus in whom glycemic Control isn't executed with the aid of using nutritional and way of life modifications. It also can be mixed with different Antihyperglycemic agents, such as metformin and insulin, in sufferers who aren't safely Controlled with the aid of using sulfonylureas alone. The powerful dosage variety is 1 to eight mg/day; however, There isn't any extensive distinction among four and eight mg/day, however it ought to be used with warning In the aged and in sufferers with renal or hepatic ailment. In scientific studies, glimepiride became Generally related to decrease threat of hypoglycemia and much less weight advantage as compared to different sulfonylureas. Glimepiride use can be more secure in sufferers with cardiovascular ailment due to its loss of adverse results on ischemic preconditioning. It is powerful in lowering fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin tiers and is a useful, cost-powerful remedy alternative for handling kind 2 diabetes mellitus.

Keywords: antihyperglycemic agents, diabetes, glimepiride, sulfonylurea, Growth factors,

Introduction:

Diabetes is a chief public fitness trouble affecting 285 million humans worldwide.The incidence of diabetes is projected to double globally through 2030. Complications of Diabetes consist of renal failure, neuropathy and peripheral vascular sickness with ability For lack of limbs, retinopathy with extended chance of blindness, and an extended chance of cardiovascular sickness and stroke, which can be associated with poorly managed diabetes.Good glycemic manipulate can save you or put off continual sickness-associated microvascular Complications as proven through the UK Prospective Diabetes Study (UKPDS) And the landmark Diabetes Control and Complications Trial.[1] The pathophysiology of kind 2 diabetes mellitus (T2DM) is characterised through Relative lower in insulin secretion and/or insulin resistance. Insulin resistance is A complicated phenomenon exacerbated through obesity, especially principal obesity, and is Believed to begin at a younger age due to the fact hyperinsulinemia is discovered in preteens while Both mother and father have diabetes.[2]

Glimepiride is a sulfonyl urea used to deal with kind –II diabetes mellitus. Molecular method of glimepiride is C24H34N4O5S with a molecular mass of approximately 490.617g/mol. It belongs to class-

II of Biopharmaceutical Classification system. It is absolutely insoluble in water, acidic media and barely soluble in diverse buffers and Organic solvents. It is run orally; insoluble in water, barely soluble in methylene Chloride(Dichloromethane), very barely soluble in methanol and soluble in Dimethyl Sulfoxide (DMSO)Glimepiride indicates low pH based solubility. In acidic and independent aqueous media, glimepiride exhibits very Poor solubility at 37C. [3]



Fig 1. Structure of Glimepiride [3].

Molecular formula of glimepiride : C24H34N4O5S

Molecular mass of glimepiride about 490.617g/mol.

Glimepiride falls in BCS Class II, it has low solubility and excessive Permeability making it tough to manufacture tablets with good Dissolution rate that consequently affects the systemic availability of Drug in the body.[4] The oral path is the often used manner for administering drugs. Among the oral dosage forms, pills are the maximum common. The global occurrence of diabetes mellitus turned into 285 million in 2010and is anticipated to growth to 380 Million through 2025, Type II diabetes debts for 85% to 95percentOf cases2. Type II diabetes mellitus is a complicated metabolic Disorder, characterised through various tiers of insulin Resistance, impaired insulin secretion, and immoderate hepatic Glucose production3. Combination cures the use of oral Antidiabetic dealers with exceptional mechanisms are validated to Decrease the risk of adverse effects and no adherence, thus Providing more optimal glycemic control3-5. The maximum Common mixture regimens encompass a sulfonylurea with Metformin 6. The mixture of Glimepiride and Metformin is said as extra powerful than Monotherapy 3,7,8. The mixture of Glimepiride and Metformin became authorized through the United States Food and Drug Administration[5]. Metformin hydrochloride is a white crystalline powder and Hygroscopic in nature. Chemically, it's far referred to as N,N-Dimethylimidodicarbonimidic diamide . It is aHypoglycemic agent, that acts through lowering hepatic glucose Production and enhancing glucose uptake in adipose tissue And skeletal muscle, which improves glucose tolerance inpatient's with kind II diabetes, decreasing each basal and postprandial plasma glucose and it exerts direct impact on Mechanism of insulin resistance [6].To choose the most appropriate treatment plan, knowing if the patient has insulin Résistance, insulin deficiency, or both is necessary. Anti-diabetic drugs are broadly divided Into non-insulin drugs such as but not limited to: insulin sensitizers (thiazolidinediones),Insulin secretagogues (sulfonylureas and glinides), which are used for type 2 diabetes, and Insulin analogs which are mainly used for type 1 diabetes [7]. Other oral anti-diabetic "non-insulin" drugs act by suppressing the excessive hepatic glucose release and enhancing the hepatic insulin sensitivity, but this class has only a little impact on peripheral insulin-mediated glucose uptake (biguanides)[8].

Glimepiride is useful in the treatment of non-insulin dependent diabetes Mellitus [1,2]. It is 1-(p-(2-(3-ethyle-4-methyl-2-oxo-3- pyrroline-1-Carboxamido) ethyl) phenyl) sulfonyl)-3-(trans-4-methylcyclohexyl) Urea which belongs to third generation of hypoglycemic sulfonylurea. The use of oral antidiabetic drugs is more preferred as compared to Other routes for the treatment of disease. The basic objective of these Drugs is to control the glycemic condition of patients by Controlling and Avoiding hypoglycemia and weight benefit that facilitates to lower the danger Of capability micro- and macro-vascular impediments . Glimepiride falls in BCS Class II, it has low solubility and excessive Permeability making it tough to fabricate capsules with accurate Dissolution rate that consequently affects the systemic availability of Drug withinside the body. In 2007, Adegbolagun et al. recommended a want to Analyze and examine the time-honored manufacturers to be had withinside the market. These Drugs have to be analyzed for his or her chemical and biopharmaceutical Equivalence, strength, pleasant, purity, and freeing profile of lively Ingredient in assessment of innovator drug.The intention of the prevailing take a look at became to evaluate the traits of Different manufacturers and newly formulated instantaneously launch capsules And compares their dissolution profile with innovator manufacturers. The Focus of the take a look at became to confirm and optimize the brand new components as Well as to assess the pleasant of time-honored manufacturers to be had in unique Market of UAE (Ras Al Khaimah, Dubai, and Abu Dhabi). These manufacturers of Glimepiride had been synthetic with the aid of using unique pharmaceutical companies, Including UAE, Saudi Arabia, Pakistan, Jordan, and India. The take a look at became Also focused on the suitability of the newly formulated capsules Which became envisioned with the aid of using increased balance studies. Consequently, The take a look at became done to offer the rule of thumb to the physicians And pharmacists on the idea of which they are able to choose the correct Brands for his or her sufferers.[9]

To select the maximum suitable remedy plan, understanding if the affected person has insulin Resistance, insulin deficiency, or each is necessary. Anti-diabetic capsules are widely divided Into non-insulin capsules which includes however now no longer restrained to: insulin sensitizers (thiazolidinediones),Insulin secretagogues (sulfonylureas and glinides), that are used for kind 2 diabetes, and Insulin analogs that are in particular used for kind 1 diabetes . Other oral anti-diabetic “Non-insulin” capsules act with the aid of using suppressing the immoderate hepatic glucose launch and improving The hepatic insulin sensitivity, however this magnificence has handiest a bit effect on peripheral insulin-Mediated glucose uptake (biguanides) . One extra magnificence of oral anti-diabetic capsules acts As competitive, reversible inhibitors of pancreatic α-amylase and membrane-certain intestinal α-glucosidase inhibitors (Acarbose).Moreover, sodium-glucose co-transporter-2 Inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin) inhibit the reabsorption of the bulk of the filtered glucose (about 90%) coming into the kidney Tubules . The mixed remedy of oral anti-diabetics, which includes metformin and sulfonylureas or metformin with thiazolidinedione, has stepped forward the care of sufferers with Diabetes.It can be used if monotherapy is failed. Despite many anti-diabetic sellers withinside the market, Sulfonylureas (Sus) are taken into consideration the maximum extensively utilized in kind 2 diabetes and were Utilized in view that 1950. Sus act in particular with the aid of using elevating the plasma insulin concentrations, specifically When residual pancreatic β-cells are present, and this increment takes place therefore due To inhibition of adenosine triphosphate (ATP)-touchy potassium channels, which leads To mobileular depolarization and insulin exocytosis in addition to suppression of hepatic clearance Of insulin . Glimepiride is a long-appearing anti-diabetic drug that belongs to Sus. It Enhances the intracellular insulin receptors’ pastime and suppresses their down-law During continual

insulin stimulation thru a mechanism concerning protein kinase C activation. Glimepiride is almost insoluble in water and has an abnormal dissolution and Absorption profile, ensuing in inconsistencies in bioavailability and drug action.[10] Self-nanoemulsifying drug shipping machine (SNEDDS) is a homogenous multi-aspect machine made of oil, surfactant, co-surfactant, and a drug which can right away dissolve to shape excellent nanoemulsion debris of nanometric variety much less than 2 hundred nm upon slight agitation in an aqueous medium. After drug administration, the agitation required to shape nanoemulsion is furnished with the aid of using the gastrointestinal tract (GIT) motility.[11]

Due to self-emulsification withinside the GIT, the drug is supplied in tiny oil droplets that beautify the dissolution profile with the aid of using offering a big interfacial floor region for the drug to partition among the oil and the GIT fluid [12].Anti-diabetic remedy calls for useful outcomes which can assist to save you diabetic complications, similarly to offering right glycemic control.Glimepiride is a second-technology sulfonylurea that stimulates pancreatic β cells to launch insulin. This agent specially stimulates insulin secretion, however has additionally been proven to have extra extra-pancreatic outcomes in animal models [13].The development of oral sustained release Formulation is an attempt to control the release of drug From the gastro intestinal tract (GIT) and maintain an Effective drug concentration in the systematic circulation For a long time. After an oral administration such a drug Will retain in the stomach, which will eventually release The drug in a controlled manner so that the drug could be Supplied continuously to its absorption sites in the GIT. Incomplete drug release from the Dosage form in the absorption zone causes diminished Efficacy of administered dose . Prolonged gastric retention improves bioavailability, Increases the duration of drug release, reduces drug waste And improves solubility of drugs that are less soluble at High pH environment (Garg and Gupta, 2008). Oral drug Delivery systems are matrix based requiring fewer unit Operations, less machineries, reduced number of employees And processing time, expanded product balance and Production rate.[14]Dissolution studies have emerged in the pharmaceutical field as a very important tool based on the fact that for a drug to be absorbed and available to the systemic circulation, it must previously be solubilized. Therefore the dissolution research are used now no longer best to evaluate batch-to-batch consistency of drug launch from strong dosage forms, however they're additionally crucial in numerous tiers of method development, for screening and right evaluation of various formulations.. Moreover, the in vitro dissolution studies obtained from dissolution rate profile has been used for the successful characterization of the in vivo behavior of drugs[15].

Mechanism of action:-

The primary mechanism of action of glimepiride for reducing blood glucose degrees appears to be depending on Stimulating the discharge of insulin from the functioning pancreatic cells. Glimepiride acts with the aid of using binding to ATP touchy Potassium channel receptors at the pancreatic mobileular surface, which reduces potassium conductance inflicting depolarization of the membrane. Calcium ion reflux is inspired with the aid of using the membrane depolarization via voltage-Sensitive calcium channels. This expanded intracellular calcium ion attention induces the secretion of insulin. It Can be hired for concomitant use with metformin, thiazolidinedione, insulin and alpha-glucosidase inhibitors for Treatment of type-2 (noninsulin dependent) diabetes mellitus. It is absolutely absorbed from the gastrointestinal tract When it’s far administered orally. The feasible aspect outcomes are intense hypoglycemic reactions with coma, seizure, or Other neurological impairmentThe other reported side effects of sulfonylureas includes clolestatic jaundice, nausea And vomiting, aplastic and hemolytic anaemia’s, agranulocytosis, generalized hypersensitivity reactions, and Rashes[16].

Glimepiride is an oral hypoglycaemic agent and is completely Absorbed after oral management however it's far Subjected to liver metabolism which contributes to its efficacy with unmarried oral management. To growth the Patient compliance and to have comfort of management, nasal gel of Glimepiride changed into organized the usage of mucoadhesive polymers which can also additionally will increase its house time there through next bioavailability. Nasal Formulation with the managed motion of drug is a superb alternative. Challenges in the development of nasal Formulation include low residence time. mucociliary clearance can be overcome by developing a mucoadhesive Formulation[17].The main objective of this present research work is to achieve sustained release Of Glimepiride and to beautify the gastrointestinal house time, for this reason mucoadhesive microbeads had been formulated with the aid of using Ionic gelation approach with HPMC and Na-CMC as coating polymers. Formulated mucoadhesive microbeads had been nicely evaluated for length distribution, tapped density entrapment efficiency, wall thickness, drug launch research, SEM and GI house time. In this gift studies affect of polymer on fee of drug launch and attention of polymer coat on fee of drug launch from the Glimepiride mucoadhesive microbeads had been studied. The fee of drug launch became determined to be reduced with the aid of using growing the attention of the coat polymer[18].

Pancreatic effects:

Glimepiride acts at ATPase-structured potassium channels In β cells of the pancreas to stimulate insulin launch. the usage of Euglycemic and hyperglycemic clamp research it's been proven To enhance each first- and second-section insulin secretion. Glimepiride binds to 65-kD proteins on β cells. In wholesome Volunteers, a linear dating became proven among serum Glimepiride concentrations and insulin launch at some point of euglyCemia and a almost linear dating below hyperglycemic Conditions.[19].Maximal glucose-decreasing hobby and insulin degree In T2DM sufferers is carried out inside 2–three hours of taking Glimepiride and may closing for 24 hours. In a 14-week scientific examine, height concentrations 2 hours after management Of 1, four, and eight mg doses of glimepiride had been related to Decreases in median fasting plasma glucose (FPG) of 43,70.5, and seventy four mg/dL, respectively. Glimepiride reduces blood glucose stages and will increase Insulin stages in blood. A three-day examine of 14 T2DM Patients determined more discounts in blood glucose (four.1 vs 1.nine mmol/L) and growth in C-peptide (1.eight vs 1.four mg/L) and Plasma insulin (forty one vs 25 mu/L) with 2 mg/day glimepiride Compared to placebo (P , 0.05).Hypoglycemia after workout whilst taking glimepiride Was determined in 167 sufferers with T2DM.This became related to a more discount in insulinemia than glibenclamide at some point of workout, notwithstanding comparable discounts in blood Glucose.Glimepiride can be taken earlier than or after breakfast With comparable results. The efficacy of two mg/day glimepiride For 2 weeks on blood glucose stages became now no longer drastically Different over a duration of 0–four hours while the drug became Given both right now earlier than breakfast or half-hour After breakfast.[20].

Extra-pancreatic effects:

After persistent management,the insulinaemic movement of sulfonylureas declines in all likelihood because of down law of sulfonylurea receptors on ß-cells, however development in glucose tolerance is maintained. In this phase, they sensitize the goal tissues (especiallyliver) to the motion of insulin. This is because of growth in variety of insulin receptorsand / or a postreceptoraction-enhancing translation of receptor activation. It is hypothesized that long time development in carbohydrate tolerance

results in a reduced insulin attention in blood which reverses the down law of insulin receptors-obvious growth of their variety. A direct more-pancreatic motion of sulfonylureas to growth insulin receptors on the right track cells and to inhibit gluconeogenesis in liver has been suggested, however seems to have little scientific relevance[21]. The more pancreatic consequences of glimepiride are just like Those of different sulfonylureas. Although peripheral tissue Response to insulin is potentiated like different Sus, the scientific relevance of this isn't but clear[22].In in vitro studies,glimepiride changed into located to be instances as robust as glibenclamide in stimulating lipogenesis and glycogenesis[23].Studies In cultured skeletal muscle additionally advise a sensitizing impact Of glimepirmode[24]. Glimepiride decreased insulin resistance And accelerated hepatic glucose disposal in animal models, But showed no effect in glucose utilization in patients with Type 1 diabetes.[25].

Cardiovascular effects :

effects to cause fewer cardiovascular effects Than other Sus. .It become determined to be related to few cardiac changes, fewer ventricular arrhythmias, and very little impact on blood stress as compared to glyburide and glipizide in animal studies.[26]. The genuine mechanism of this Difference in cardiovascular hobby isn't clear; however, Involvement of adenosine triphosphate-touchy potassium (KATP) channels are concept to play an vital role. Unlike different Sus, glimepiride does now no longer impair ischemic Preconditioning of cardiac myocytes. Ischemic preconditioning is an adaptive phenomenon which happens in Response to an ischemic occasion and delays infarct improvement in the course of next ischemic episodes, which can also additionally assist Limit tissue harm[27]. The postulated mechanism includes Selective interplay of glimepiride with sacrolemmal ATP established potassium channels in cardiac myocytes Rather than mitochondrial channels. Evidence shows That glimepiride preserves myocardial preconditioning, a Protective mechanism that limits harm withinside the occasion of An ischemic event.Data from animal studies suggests that the effects of Glimepiride on KATP channels, Cardiac vessels, or blood Vessels had been insignificant in comparison to that as a result of the Same dosage of glyburide... Similarly, glimepiride has much less Of an impact in selling ST phase elevation, improving Coronary resistance and decreasing coronary blood go with the drift in comparison to glyburide or gliclazide. Thus, the usage of glimepiride can be more secure than different Sus In cardiac sufferers because of its loss of negative consequences on Cardiac preconditioning .

Clinical efficacy:

The drug has been assessed in placebo-managed research as monotherapy and in comparison with different SUs and insulin in T2DM sufferers. Most research tested FPG, post-prandial glucose (PPG), and HbA1c. Some research protected plasma lipids, serum insulin, or fasting C-peptide levels.[28].The reason of this observe changed into to enhance the solubility, dissolution charge and sustained launch of the drug. Glimepiride cubosomes had been organized through Top down technique using Glycerylmonooleate (GMO) as lipid Phase vehicle, Poloxamer 407 as stabilizer and distilled water as aqueous phase. The resultant cubosome Dispersion had been characterised through encapsulation efficiency, In-vitro drug launch, particle length, zeta ability, FTIR and SEM. Optimized formulation (F5) confirmed a most drug launch of 71 % in 6 hours, particle length Of 88.7nm and zeta ability of 43.6 mV. Glimepiride cubosomal Capsules had been organized with the optimized Cubosomal dispersion, through the usage of a brand new method starch and aerosil had been used as granulating retailers to reap a Wet mass. Then the moist mass changed into handed via sieve no. sixteen to shape granules. Then the granules

had been dried in Hot air oven. The dried granules had been stuffed into capsules. The granules had been evaluated for SEM, zeta ability, Flow homes and In-vitro drug launch. Optimized pill formulation (C2) consists of starch confirmed a Maximum drug launch of 49 % in 6 hours, particle length of 213nm and zeta ability of -159 mV. In-vitroRelease kinetics exhibited sustained launch up to six hours and accompanied non- Fickian diffusion. Results propose That GMO cubosomes, as lipid nanovectors, may want to extensively decorate oral efficacy whilst in comparison to Glimepiride powder[29].

Glimepiride acts as an insulin secretagogue. To offer the sufferers with the maximum handy mode of Administration, there has been a want to increase instantaneously launch dosage shape, especially one which disintegrates Rapidly and disperses and facilitates in improving the Bioavailability of the drug. Glimepiride instantaneously launch Tablets had been formulated through the usage of moist granulation approach and povidone k30, starch as binders, croscarmellose Sodium, sodium starch glycolate, crospovidone as disintegrants, lactose monohydrate as diluent and magnesium Stearate as lubricant.The tablets were evaluated forpre-compression and post-compression parameters after Conducting preformulation studies. All the parameters were within the pharmacopoeial limits and the drug Disintegrate on time was less and the In-vitro dissolution studies showed that the drug release was fast[30].

Materials and Methods :

Metformin hydrochloride (Workhardt Research centre,India), Glimepiride (Kores India Ltd., India) were received As gift sample. Lactose monohydrates (DMV internationals,India), Microcrystalline cellulose (Weiming Pharmaceuticals, India), Crospovidone (BASF South East Asia Pvt Ltd., India), Povidone (BASF South East Asia Pvt Ltd., India), Sodium starch glycolate (DMV internationals,India), Magnesium stearate (Vijlak Pharma, India),Methylene chloride (Chempant samar, India), Hydroxy Propyl methyl cellulose (Colorcon Asia Pvt, Ltd., India),Titanium dioxide (Cobot Sanmar Ltd., India), Talc (Prakash & Co., India), Propylene glycol (Vasuda Chemicals Pvt. Ltd., India) and polysorbate 80 (Sigachi chloro Pvt Ltd. India) were commercially procured and used in this study [31].

Method of analysis:

To achieve the consistent, reliable, and accurate data for the analysis of drug in dosage form, reported high-performance liquid chromatography (HPLC) analytical method was first validated as per ICH guideline and was then used to estimate glimepiride in marketed as well as in newly formulated tablets [32].

Film coating of Tablets:

Film coating of the fabricated drugs turned into hired through Using the numerous excipients as consistent with the components given in Table 2. Weighed amount of Hydroxy propyl methyl Cellulose (HPMC) 15cps turned into dispersed withinside the eighty% of the Required amount of purified water with the assist of Mechanical stirrer. Weighed amount of talc and titanium Dioxide had been triturated in a mortar with closing 20% of Purified water and brought to the above answer. After 10min, propylene glycol and polysorbate eighty had been brought to The above mixture. This solution was mixed for five Minutes and filtered through 200 mesh nylon cloth. The Filtered solution was used coating the Metformin Hydrochloride and Glimepiride tablets.

Sl.No	Ingredients	Quantity For One Thousand Tablets (in gms)
1	HPMC 15cps	5.26
2	Titanium dioxide	2.63
3	Talc	1.05
4	Propylene glycol	0.5
5	Polysorbate 80	0.5
6	Purified water	73.69

Table: The composition of coating solution of Metformin hydrochloride and Glimepiride tablets

Bulk Density:

Weighed quantity of granules was transferred into a 50ml Measuring cylinder without tapping and the volume Occupied by granules was measured. Bulk density was Measured by using following formula ;

Þb = M / V0

Where,

Þb = Bulk Density

M = Mass of blend

V0 = Untapped volume

Tapped Density:

Weighed quantity of granules was taken into graduated Cylinder, volume occupied by granules was noted down.

Then, cylinder was subjected to 50 taps in tapped density Tester (Thermonik, Campbel Electronics, India). The Percentage volume variation was calculated by the Following formula

Þt = M / Vt

Where,

Þt = Tapped Density

M = Mass of blend

Vt = Tapped volume

Compressibility Index:

Compressibility is the ability of granules to decrease in Volume under pressure using bulk density and tapped Density the percentage compressibility of granules were Determined, which is given as carr's compressibility index.

CI = (Þt – Þb/ Þt) × 100.

Where,

CI = Compressibility index

Þb = Bulk density

Þt = Tapped density

Following table shows the percentage compressibility index an Flow characteristics.

Compressibility Index	Type of Flow
1-10	Excellent
11-15	Good
16-20	Fair
21-25	Passable
26-31	Poor
32-37	Very Poor
>38	Extremely Poor

Table: Carr's Index with corresponding Flow character

Hausner's ratio:

It was determined by the ratio of tapped density and bulk Density. Table 4 shows the flow characteristics and Corresponding Hausner's ratio

Hausner's ratio = Þt/ Þb

Where,

Þt = Tapped density

Þb = Bulk density

Hausner's ratio	Type of Flow
1-1.1	Excellent
1.12 – 1.18	Good
1.19 – 1.25	Fair
1.26 – 1.34	Passable
1.35 – 1.45	Poor
1.46 – 1.59	Very Poor
>1.6	Extremely Poor

Table: Hausner's ratio with corresponding Flow character

Evaluation of Tablets:

The formulated tablets were evaluated for the following Physicochemical parameters

1. Hardness: Tablets require certain amount of strength to have a Resistance from breakage, while transportation and handling Before use. It was measured by Monsanto Hardness Tester(Tab machines, India).

2. Thickness: The thickness of tablet can vary without any change in Weight. This is commonly because of the variations of density of Granules, stress carried out for compression and the rate of Compression It was measured by vernier caliper (Mitutoyo,Japan).

3. Friability: Friability was performed by using friability test apparatus (Electrolab, ET2, India). Specified number of tablets were Weighed and placed in the tumbling chamber and roated for Four minutes at a speed of 25 rpm. During each revolution,Tablets fall from a distance of 6 inches to undergo shock. After a hundred revolutions the drugs are dusted and reweighed.The loss in weight indicates friability and loss of less than 1% in weight is considered to be acceptable. It was Determined by the following formula.

$F = W1 – W2/ W1 \times 100$

Where

W1 = Initial weight of tablets

W2 = Final weight of tablets

4. Weight variation test: Twenty capsules have been decided on randomly and weighed Individually. Average weight of capsules have been calculated and Compared with that of the man or woman capsules. Weight not More than two of the individual weight deviate .[33].

5. Disintegration time:

The disintegration time was performed using an USP Disintegration test apparatus (TD2, Tab machines, India)With distilled water at 37±0.5°C. The disintegration time Was taken to be the time whilst no granules of any capsules Were left at the mesh of the apparatus. The time reported to Obtain complete disintegration of six tablets were recorded And mean Val spectrophotometer.[32]. Dissolution exams of glimepiride sustained launch drugs have been done consistent with the approach of Hermann et al. (2005). Phosphate buffer of pH 6.eight changed into used as dissolution medium and the test changed into done with the USP equipment 2 (paddle approach) at 50 rpm and 37º ± 0.5 °C for eight hrs. Released drug samples from the dissolution medium have been assayed at 228 nm the use of UV spectrophotometer.[34].

6. Stability studies:

The cause of the steadiness checking out is to offer proof On how the great of a drug substance or drug product Varies with time below the have an impact on of numerous Environmental elements along with temperature, humidity and Light and to establish a retest for the drug substance or a self Life for the drug product and recommended storage Conditions. In order to determine the change on storage,Stability study was carried out a 25°C / 60% RH and 40°C /75% RH in a stability chamber. Samples were withdrawn at Regular intervals. Formulation was evaluated for changes in Hardness, thickness, disintegration time and in vitro release Studies.[35]. One of the most important pharmaceutical parameters to assess the quality of any newly designed formulation is the stability of the drug in its dosage form. After the quality assessment of tablets, G10 was kept for stability for 3 months (0, 1, 2, and 3 months) under accelerated conditions, 40±2°C; 75±5% R.H, as per the ICH guidelines [36].

7. Drug release kinetics studies:

The dissolution tests were carried out using the Type-II apparatus (paddle), at 75 rpm. Dissolution was done in phosphate buffer (pH 7.8) With multipoint sampling at different time intervals of 5, 10, 15, 20, 30, And 45 min and analyzed by HPLC method at λmax = 228 nm.The dissolution data of prototype tablets (G10) were analyzed with Various kinetic equations in comparison to generic (Glim-B – H) and Innovator tablets (Glim-A), to understand the kinetic release and ability Of the tablets [37].

Instrumentation:

A Lab India 3000+ UV-Visible Spectrophotometer with spectral bandwidth of 2.0 nm and Wavelength accuracy of ±0.5 nm with automatic wavelength correction and a pair of 10 mm Quartz cells were used for the absorbance measurements connected with UVWIN version 5.2.0 software. The dissolution studies were performed on Electro lab, TDT-08L USP Dissolution apparatus.

HPLC instrumentation and chromatographic conditions:

The HPLC analysis was carried out on Shimadzu HPLC-20 AD series binary gradient pump with Shimadzu SPD-M20A detector (Tokyo, Japan). The column used Was Phenomenex Luna C18 (2) (250 × 4.6 mm) packed With five µm particles. The injection quantity of pattern 20 µL changed into utilized in all of the experiments. In an isocratic Mobile section containing acetonitrile and 0.2 M phosphate buffer (pH 7.4), 40:60 (v/v) changed into pumped thru The column with a float price of one mL/min and the quantification changed into accomplished at 228 nm the usage of PDA detector. The cell section changed into filtered thru a 0.45-µm membrane clear out and degassed earlier than use.

Preparation of standard solution:

Standard stock solution (100 µg/mL) was prepared by transferring 10 mg of glimepiride into A 100 mL volumetric flask, 30 mL of 0.1 M sodium hydroxide was added, and the mixture Was sonicated to dissolve and make up the volume with methanol. Aliquots of these standard Solution was transferred using A-grade bulb pipette into 100 mL volumetric flasks and made Up to volume me with methanol to get final concentration of 6.0 – 14.0 µg/mL[38].

inventory answer of a hundred µg/mL changed into organized via way of means of moving 10 mg of GLM right into a a hundred-mL volumetric flask;30 mL of 0.1 N NaOH changed into added, and the combination changed into Sonicated to dissolve and the very last quantity of the answer changed into made up with HPLC grade methanol. The inventory Solution changed into covered from mild the usage of aluminum foil And aliquots of the usual inventory answer of GLM have been Transferred the usage of A-grade bulb pipettes into 10-mL volumetric flasks and the answers the Range of 0.2, 0.4, 0.8, 0.9, 1.2, 1.4, and 2



Figure : UV-spectra of glimepiride against methanol as blank.

Preparation of liquid self-nanoemulsifying drug delivery System and self-nanoemulsifying powder formulation:

The vehicle (sesame oil), surfactant (Tween® 20), and coSurfactants (PEG 400) had been decided on for the coaching Of self-nanoemulsifying drug transport systems (SNEDDS).The components changed into organized with the aid of using dissolving GLM withinside the Mixture of oil, surfactant, and co-surfactant as it should be Weighed in glass vials. Then, the additives had been combined By mild stirring and vortex blending the usage of vortex mixer (REMI CM 101DX, REMI Equipment, Mumbai, India) And heated at 50 °C in an isothermal water tubtub to reap A homogenous isotropic mixture. The very last components Was inspected for symptoms and symptoms of turbidity or section separation And drug precipitation previous to self-emulsification. The Formulation changed into saved at ambient temperature for in addition Use. The best approach to transform liquid SNEDDS to SNEP is, with the aid of using adsorption onto the floor of carriers. In the Present study, Aerosil® two hundred changed into used as an adsorption carrier. SNEP changed into organized with the aid of using blending liquid SNEDDS containing GLM with Aerosil® two hundred in 1:1 proportion. In brief,Liquid SNEDDS changed into introduced drop clever over Aerosil® two hundred Contained in a huge porcelain dish. After every addition, Mixture changed into homogenized the usage of glass rod to make sure uniform distribution of components. Resultant damp mass changed into surpassed via sieve no. a hundred and twenty and dried at ambient temperature. Then the dose-equal free-float powder changed into crammed into tough gelatin drugs and saved till in addition use

Dissolution release study of pure drug, marketed and SNEPS formulations:

The dissolution research of GLM-loaded SNEP system turned into completed in a USP-II dissolution take a look at apparatus (DS 8000, LABINDIA, Mumbai, India). The dissolution Studies have been carried out in line with the dissolution Procedure endorsed for single-entity merchandise in 900 mL of 0.1 N HCl (seventy five rpm). The temperature of The mobileular turned into maintained at 37 ± 0.five °C through the use of a Thermostatic bath. At predetermined time intervals (0,five, 10, 15, 30, 60, 90, and a hundred and twenty min) an aliquot (five mL) Of the pattern turned into withdrawn from every vessel and Immediately changed with an same extent of clean medium to keep sink conditions. The samples accrued Were filtered thru a membrane filter (0.forty five µm) and in addition analyzed through HPLC. In order to achieve the dissolution Profile, the cumulative percent of drug launched turned into Plotted in opposition to time (min). Method validation: The optimized chromatographic technique turned into absolutely tested in line with the tactics defined in ICH pointers Q2 (R1) for the validation of analytical methods

Table :Optimized chromatographic condition

Stationary phase (column)	Phenomenex luna C1 (250 × 4.5 mm) packed with 5 µm particles
Mobile phase	Acetonitrile, 0.2 M phosphate buffer (pH 7.4) 40:60 (*v/v*)
Detection wave length (nm)	228
Run time (min)	10
Flow rate (mL/min)	1
Volume of injection loop (µL)	20
Column temperature	Ambient
Glimepiride R_t (min)	3.543

Linearity and range: Standard inventory answer turned into diluted to put together answers 2Containing 0.2 to two µg/mL of the GLM. The answers Were injected in triplicate into the HPLC column, keepIng the injection quantity constant (20 µL).

System suitability: Twenty microliters of the same old answer (1.2 µg/mL) Was injected six instances beneath optimized chromatographic Conditions to assess the suitability of the system [39].

Limit of detection and restriction of quantification:

The restriction of detection (LOD) is the bottom quantity of Analyte that may be detected in a sample, however now no longer always quantified, beneathneath the said experimental situations'. The restriction of quantification (LOQ) turned into diagnosed As the bottom plasma awareness of the same old curve That can be quantified with applicable accuracy, precision, and variability. They are decided via way of means of the signal-To-noise method. Standard inventory answers of GLM (1 mg/mL) had been organized. Standard answers of GLM (0.2, 0.4, 0.8, 0.9, 1.2,1.4, and a pair of µg/mL) had been organized via way of means of diluting the same old inventory answers with cellular phase. The LOD and LOQ GLM beneath Neath the prevailing chromatographic situations had been anticipated at a signal-to-noise ratio (S/N) of 3:1 and 10:1 respectively, via way of means of injecting a chain of diluted answers with regarded concentrations. The LOD and LOQ for GLM had been observed to be 0.38 and 1.17 µg/mL,respectively [40].

Study protocol :

All sufferers acquired remedy with glimepiride after examine Entry. Glimepiride turned into commenced as: 1) a brand new medicine in Diabetic sufferers receiving diet/workout remedy however no Anti-diabetic agents; 2) extra remedy in aggregate With α-GIs in sufferers with poorly managed glucose; or in change for first era sulfonylurea agents,Such as glibenclamide or gliclazide in sufferers with Poorly managed glucose. The dose of glimepiride turned into Started at 1 mg every day and improved up to six mg every day till a Value of HbA1c < 6.five% turned into finished in sufferers who acquired glimepiride as a brand new medicine or an extra Therapy to α-GIs. If the glimepiride turned into given in area of Glibenclamide or gliclazide, the beginning dose of glimepiride Was determined via way of means of regarding preceding reviews indicating That 1 mg of glimepiride corresponded to 1.five mg of Glibenclamide or 20 mg of gliclazide. Adverse activities had been Recorded continuously. In all the access sufferers, diverse Blood biomarkers associated with cardiovascular pathophysiology had been measured at baseline earlier than beginning glimepiride Treatment and 24 weeks after the begin of glimepiride Treatment.

Measurement of advanced glycation end products :

The concentrations of glyceraldehyde-derived superior Glycation cease products (glycer-AGE), one of the poisonous AGE Present withinside the serum, have been measured with a aggressive ELISA the use of an immunopurified glycer-AGE antibody . In brief, 96-nicely microtiter plates have been covered with 1 µg/ml Glycer-AGE-bovine serum albumin (BSA) in step with nicely, and Were stored in a single day in a chilly room. The wells have been Washed 3 instances with 0.three ml of phosphate-buffered saline (PBS)-Tween-20. Wells have been then blocked with the aid of using incubation for 1 h with 0.2 ml of PBS containing 1% BSA. After washing With PBS-Tween-20, check samples (50 µl) have been brought to Each nicely as a competitor for fifty µl of the glycer-AGE Antibody (1:1000), observed

with the aid of using incubation for two hr at room Temperature with mild shaking with the aid of using a horizontal rotary Shaker The wells were then washed with PBS-Tween-20 And developed with an alkaline-phosphatase-linked ant Rabbit IgG utilizing p-nitrophenyl phosphate as a coloriMetric substrate. The consequences are expressed as glycer-AGE Units (U) according to milliliter of serum, with 1 U corresponding To 1 µg of glycer-AGE-BSA standard. The sensitivity and Intra- and inter-assay coefficients of variant had been 0.01 U/ml, 6.2 and 8.8%, respectively. The stage of the soluble Form of the receptor for AGE (sRAGE) changed into measured Using an ELISA kit (R & D Systems Inc, Minneapolis,MN, USA), as defined previously [41]

Dosage and administration:

The beginning dose of glimepiride is 1–2 mg usually Taken earlier than breakfast. The dose is adjusted consistent with Self-tracking of blood glucose ranges and is steadily Increased till glycemic manage is achieved. The most advocated dosage is eight mg/day, despite the fact that doses Up to 32 mg/day had been utilized in scientific trials. Typical Maintenance dosages are 1–four mg/day. However, better dosages' (6–eight mg/day) had been observed to be related to Reduced suggest HbA1c earlier than and after remedy. It can also additionally Also be mixed with different remedy modalities for T2DM, Including insulin in sufferers who aren't managed with Sus. However, the mixture of insulin and glimepiride Requires a decrease preliminary dose of insulin[42].Glimepiride is began out at a dose of one to 2mg as soon as every day with breakfast. Regular blood glucose and HbA1c level monitoring is used to guide therapy. Dosages are titrated each 1 to two weeks till glycaemic manage or most dosages (8 mg/day in the US, 6 mg/day in the UK) are reached.Usual maintenance dosages are 1 to 4 mg/day. In the US, glimepiride 8 mg/day may be combined with insulin in patients with secondary sulphonylurea failure. Patients receiving other sulphonyl urea may be switched to glimepiride without a transition period. Glimepiride can be used carefully in elderly, malnourished or debilitated sufferers and people with renalrenalor hepatic insufficiency, but is not recommended for use in children or in pregnant or breastfeeding women.[43].

Glimepiride in combination with insulin:

Patients who fail to attain proper glycemic manage on mixture remedy might also additionally require insulin. Forty Glimepiride is the Only SU presently permitted via way o**f** means of the FDA for mixture Therapy with insulin. Several research have proven that a Combination of insulin and glimepiride effects in a reduced Requirement of insulin and proper glycemic manage.[44].In a 24-week take a look at of overweight sufferers now no longer safely Controlled via way of means of most doses of Sus, addition of insulin Was in comparison to insulin + placebo.41 Subjects have been randomized to get hold of insulin and both glimepiride sixteen mg/day or Placebo, and the insulin dosage turned into titrated to attain FPG Of 100–120mg/dL. 100–120 mg/dL. The two groups showed similar HbA1 And FPG at the end of the study period However, the institution Receiving insulin + glimepiride required much less insulin (forty eight vs seventy eight U/day) and FPG turned into reduced greater unexpectedly after 2 and four weeks of remedy than withinside the insulin/placebo

Advantages of glimepiride compared to other Sus:

Hypoglycemia and weight benefit are vital disadvantages' of SU therapy; however, the precise homes of Glimepiride might also additionally offer benefits over different presently Available insulin secretagogues. Glimepiride is commonly well-tolerated, and its protection Has been reviewed in

numerous randomized medical research Involving greater than 5000 patients. Data from those medical Trials suggest that the general incidences of destructive activities Associated with glimepiride are commonly decrease in comparison With different Sus [46].[47].

Conclusion:

Glimepiride is a second-generation sulfonylurea which can be used as monotherapy or in combination with other antihyperglycemic agents, including insulin. It is the only SU currently recommended for use with insulin. The protection and efficacy of glimepiride has been showed in diverse managed studies and it is associated with a lower risk of hypoglycemia and weight gain compared to other Sus. Glimepiride is effective in reducing FPG, PPG, and HbA1c levels and is a useful, cost-effective treatment option for managing T2DM.

The method relies on the use of Simple working procedure; hence, this method can be routinely employed in quality control for analysis of GLM in Pharmaceutical dosage forms and dissolution studies. The proposed approach became rapid, accurate, precise, and Sensitive for the quantification of GLM from its pharma ceutical dosage paperwork. The approach is predicated on the usage of Simple operating method; hence, this approach may be mechanically hired in great manage for evaluation of GLM in Pharmaceutical dosage paperwork and dissolution studies

References:

1. Abdul Basit,Musarrat Riaz,Asher Fawwad Vascular Health and Risk Management,4 September 2012,463-472.
2. Fujimoto WY, Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW. Metabolic and adipose risk factors for NIDDM and coronary disease in third-generation Japanese-American men and women with impaired glucose tolerance. Diabetologia. 1994;37(5):524–532.
3. Anupamaa Tiwari, Manoj Kumar Mishra, Kanika Nayak, GarimaVerma, Sunil Kumar Yadav and Ashutosh Shukla Review Article on Glimeperide Oral Hypoglycemic Drug, Int. J. Adv. Res. 4(11), 920-927.
4. Adegbolagun OA, Olalade OA, Osumah SE. Comparative evaluation of the biopharmaceutical and chemical equivalence of some commercially available brands of ciprofloxacin hydrochloride tablets. Trop J Pharm Res 2007; 6:737-45.
5. M. Manikandan, K. Kannan, S. Selvamuthukumar, R. Manavalan,Design, Development and Evaluation of Metformin Hydrochloride and Glimepiride Immediate Release Tablets, Research J. Pharm. and Tech. 5(4): April 2012
6. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. American Journal of Medicine. 102; 1997: 99–110.
7. Tahrani, A.A Barnett, A.H.; Bailey, C.J. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Nat. Rev. Endocrinol. 2016, 12, 566–592.
8. Foretz, M.; Guigas, B.; Bertrand, L.; Pollak, M.; Viollet, B. Metformin: From Mechanisms of Action to Therapies. Cell Metab. 2014,20, 953–966.
9. Shahanaz usman , M. bassam Ismail shehada, anab ,quamrul Islam pharmaceutical quality assessment of glimepiride tablets – comparison of brands and newly formulated tablets with innovator, Asian Journal of pharmaceutical and clinical research Vol 14, Issue 10, 2021

10. Tarek A. Ahmed , Hanadi A. Alotaibi , Alshaimaa M. Almehmady Influences of Glimepiride Self-Nanoemulsifying Drug Delivery System Loaded Liquisolid Tablets on the Hypoglycemic Activity and Pancreatic Histopathological Changes in Streptozotocin-Induced Hyperglycemic Rats, Nanomaterials 2022.12, 3966
11. Nasr, A.; Gardouh, A.; Ghorab, M. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of glimepiride:Development and antidiabetic activity in albino rabbites. Drug Deliv. 2015, 22, 499–508.
12. Cherniakov, I.; Domb, A.J.; Hoffman, A. Self-nano-emulsifying drug delivery systems: An update of the biopharmaceutical Aspects. Expert Opin. Drug. Deliv. 2015, 12, 1121–1133
13. Muller G, Wied S: The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation and dephosphorylation in insulin-resistant rat adipocytes in vitro.Diabetes 1993, 42:1852–1867.
14. Samira Karim,Mohiuddin Ahmed Bhuiyan and Md. Sohel Rana, Formulation and In vitro Evaluation of Glimepiride Sustained Release Tablets: Comparison with Immediate Release Tablets Bangladesh Pharmaceutical Journal 18(2),2015: 157-162,
15. FDA 1997a. Center for Drug Evaluation and Research, Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, August-1997.
16. Venkateswarlu G, Srinivasa RP, Nageswara RP, Ramakrishna G, Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LCMS/ MS and its application to a human pharmacokinetic study,J Pharm. Sci. 2013;3: 9-19.
17. Akash BP, Gondkari SB, Saudagari RB, Design and evaluation of mucoadhesive gel of glimepiride for nasal delivery, American J Pharmacy Health Res. 2013; 1: 67-77.
18. Tejakrishna M, Kishore VS, Rao KVSP,Sudheer B, Formulation and evaluation of mucoadhesive microbeads of Glimepiride, Sch. Acad. J. Pharm. 2013; 2:199-208.
19. Goldberg RB, Holvey SM, Schneider J. The Glimepiride Protocol Study Group. A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:847–856.
20. Abdul Basit,Musarrat Riaz,Asher Fawwad ,Glimepiride: evidence-based facts, trends, and observations, Vascular Health and Risk Management 2012:8 463–472.
21. Tripathi KD, Essentials of medical pharmacology, 6th Edition, 2008, Jaypeebrothers medical publishers (P) Limited, pp: 266-267.
22. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med. 2000;6(11):907–933.
23. Végh A, Papp JG. Haemodynamic and other effects of sulphonyl urea drugs on the heart. Diabetes Res Clin Pract. 1996;(Suppl 31):S43–S53.
24. Müller G, Wied S, Straub J, Jung C. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur J Pharmacol. 2008;597(1–3):6–18.
25. Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010;6(2):225–235.
26. Végh A, Papp JG. Haemodynamic and other effects of sulphonylurea drugs On the heart. Diabetes Res Clin Pract. 1996;(Suppl 31):S43–S53.

27. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103(25):3111–3116.
28. Abdul Basit, Musarrat Riaz, Asher Fawwad, Glimepiride: evidence-based facts, trends, and observations. Vascular Health and Risk Management 2012:8 463–472
29. Venkatesh B, Indira S,Prathima S, Formulation and evaluation of glimepiride oral capsules, Int. J Pharm. Sci. Invention 2014; 3: 1-13.
30. Harihar PM, Duraivel S, Effect of different binders and super disintegrants on formulation of glimepiride immediate release tablets by wet granulation method, Int. J Pharm. Clinical Res. 2012; 4: 44-47.
31. M. Manikandan, K. Kannan, S. Selvamuthukumar, R. Manavalan,Design, Development and Evaluation of Metformin Hydrochloride and Glimepiride Immediate Release Tablets Research J. Pharm. and Tech. 5(4): April 2012
32. Shehada MB, Usman S, Akram M, Usman A. Innovative approaches to enhance dissolution rate of a hydrophobic drug glimepiride.J Pharmaceu Pharmacol 2020; 8:1-10.
33. M. Manikandan, K. Kannan, S. Selvamuthukumar, R. Manavalan Design, Development and Evaluation of Metformin Hydrochloride and Glimepiride Immediate Release Tablets Research J. Pharm. and Tech. 5(4): April 2012
34. Swati Jagdale et al. Formulation and evaluation of chewable tablet of levamisole. International Journal of Research in Pharmaceutical Sciences. 1(3); 2010: 282-289
35. Samira Karim, Mohiuddin Ahmed Bhuiyan, Formulation and In vitro Evaluation of Glimepiride Sustained Release Tablets: Comparison with Immediate Release Tablets Bangladesh Pharmaceutical Journal 18(2);2015: 157-162,
36. Ngwuluka NC et al. Formulation and evaluation of paracetamol tablets manufactured using the dried fruit of Phoenix dactylifera Linn as an excipient. Research in Pharmaceutical Biotechnology. 2(3); 2010: 25-32.
37. Guidance for Industry: Stability Testing of New Drug Substances and Products ICH Q1A (R2). FDA; 2003. Available from: https://www.fda.gov/vaccines-blood-biologics/biologicsguidances/tissue-guidances.
38. Oribe T, Yamada M, Takeuchi K, Tsunemi S, Imasaka K, Shirakura O, et al. Formulation and in vivo-in vitro correlation of the dissolution property of lemildipine solid dispersions-incorporated suppositories. Int J Pharm 1995; 124:27-35
39. Madhusudhana reddy induri, bhagavan raju m, rajendra Prasad y and pavankumar reddy, Development and Validation of A Spectrophotometric Method for Quantification and Dissolution Studies of Glimepiride in Tablets Coden Ecjhao, E-Journal of Chemistry 2012, 9(2), 993-998
40. Abdul Bari Mohd, Krishna Sanka, Rakesh Gullapellya, Prakash V Diwan1 and Nalini ShastriDevelopment and validation of RP-HPLC method for glimepiride and its application for a novel self-nanoemulsifying powder (SNEP) formulation analysis and dissolution study Mohd et al. Journal of Analytical Science and Technology 2014, 5:27
41. Yamagishi S, Adachi H, Nakamura K: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006, 55:1227–1231.

42. eon HJ, Oh TK. Comparison of Vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J. 2011;35:529–535.
43. H D Langtry, J A Balfour,Glimepiride. A review of its use in the management of type 2 diabetes mellitus, 1998 Apr;55(4):563-84.
44. Schernthaner G, Grimaldi A, Di-Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34:535–542.
45. Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: Safe, reliable, and becoming routine. Horm Metab Res. 1996;28: 430–433
46. Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk Groups of NIDDM patients. Horm Metab Res. 1996;28(9):434–439.
47. Goldberg RB, Holvey SM, Schneider J. The Glimepiride Protocol #201 Study Group. A dose response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:847–856.